Literature DB >> 28360754

Clinically Isolated Syndromes: Clinical Characteristics, Differential Diagnosis, and Management.

Hüsnü Efendi1.   

Abstract

Clinically isolated syndrome (CIS) is a term that describes the first clinical onset of potential multiple sclerosis (MS). The term CIS is typically applied to young adults with episodes of acute or subacute onset, which reaches a peak quite rapidly within 2-3 weeks. In 85% of young adults who develop MS, onset occurs with an acute, CIS of the optic nerves, brainstem, or spinal cord. When clinically silent brain lesions are seen on MRI, the likelihood of developing MS is high. Because no single clinical feature or diagnostic test is sufficient for the diagnosis of CIS, diagnostic criteria have included a combination of both clinical and paraclinical studies. Diagnostic criteria from the International Panel of McDonald and colleagues incorporate MRI evidence of dissemination in time and space to allow a diagnosis of definite MS in patients with CIS. As CIS is typically the earliest clinical expression of MS, research on patients with CIS may provide new insights into early pathological changes and pathogenetic mechanisms that might affect the course of the disorder. With recent improvements in diagnosis and the advent of disease-modifying treatments for MS, there has been growing interest and research in patients with CIS.

Entities:  

Keywords:  Clinically isolated syndrome; diagnostic criteria; multiple sclerosis

Year:  2015        PMID: 28360754      PMCID: PMC5353226          DOI: 10.5152/npa.2015.12608

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  28 in total

1.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors:  L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal:  N Engl J Med       Date:  2000-09-28       Impact factor: 91.245

Review 2.  Immunotherapy for clinically isolated syndrome? Not necessarily...

Authors:  Aksel Siva
Journal:  Nat Clin Pract Neurol       Date:  2008-03-25

Review 3.  Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.

Authors:  D S Goodin; D Bates
Journal:  Mult Scler       Date:  2009-10       Impact factor: 6.312

4.  Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria.

Authors:  T Fangerau; S Schimrigk; M Haupts; M Kaeder; G Ahle; N Brune; K Klinkenberg; S Kotterba; M Möhring; E Sindern
Journal:  Acta Neurol Scand       Date:  2004-06       Impact factor: 3.209

5.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?

Authors:  M Tintoré; A Rovira; J Río; C Tur; R Pelayo; C Nos; N Téllez; H Perkal; M Comabella; J Sastre-Garriga; X Montalban
Journal:  Neurology       Date:  2007-09-19       Impact factor: 9.910

6.  Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.

Authors:  P O'Connor; R P Kinkel; M Kremenchutzky
Journal:  Mult Scler       Date:  2009-06       Impact factor: 6.312

Review 7.  Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management.

Authors:  David Miller; Frederik Barkhof; Xavier Montalban; Alan Thompson; Massimo Filippi
Journal:  Lancet Neurol       Date:  2005-06       Impact factor: 44.182

Review 8.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.

Authors:  David Miller; Frederik Barkhof; Xavier Montalban; Alan Thompson; Massimo Filippi
Journal:  Lancet Neurol       Date:  2005-05       Impact factor: 44.182

9.  New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes.

Authors:  Catherine M Dalton; Peter A Brex; Katherine A Miszkiel; Kryshani Fernando; David G MacManus; Gordon T Plant; Alan J Thompson; David H Miller
Journal:  Ann Neurol       Date:  2003-05       Impact factor: 10.422

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  6 in total

Review 1.  Metabolomic Biomarkers of Multiple Sclerosis: A Systematic Review.

Authors:  Lachlan Porter; Alireza Shoushtarizadeh; George A Jelinek; Chelsea R Brown; Chai K Lim; Alysha M de Livera; Kelly R Jacobs; Tracey J Weiland
Journal:  Front Mol Biosci       Date:  2020-12-14

2.  Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis.

Authors:  Fay Probert; Tianrong Yeo; Yifan Zhou; Megan Sealey; Siddharth Arora; Jacqueline Palace; Timothy D W Claridge; Rainer Hillenbrand; Johanna Oechtering; David Leppert; Jens Kuhle; Daniel C Anthony
Journal:  Brain Commun       Date:  2021-04-19

3.  Brainstem syndrome at onset is related to an early MS diagnosis in Peru: A national referral center cohort.

Authors:  César Caparó-Zamalloa; Sheila Castro-Suarez; Jaqueline Cortez-Escalante; Wilfor Aguirre-Quispe; Erik Guevara-Silva; Victor Osorio-Marcatinco; María Meza-Vega
Journal:  Heliyon       Date:  2021-09-29

Review 4.  Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.

Authors:  George Saitakis; Bart K Chwalisz
Journal:  Int J Mol Sci       Date:  2022-08-29       Impact factor: 6.208

Review 5.  Anti-inflammatory and Neuroprotective Agents in Clinical Trials for CNS Disease and Injury: Where Do We Go From Here?

Authors:  Khalil Mallah; Christine Couch; Davis M Borucki; Amer Toutonji; Mohammed Alshareef; Stephen Tomlinson
Journal:  Front Immunol       Date:  2020-09-10       Impact factor: 7.561

Review 6.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.